- Home
- REX vs NTLA Comparison
REX vs NTLA Comparison
Compare REX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- NTLA
- Stock Information
- Founded
- REX 1980
- NTLA 2014
- Country
- REX United States
- NTLA United States
- Employees
- REX N/A
- NTLA N/A
- Industry
- REX Major Chemicals
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- REX Industrials
- NTLA Health Care
- Exchange
- REX Nasdaq
- NTLA Nasdaq
- Market Cap
- REX 1.0B
- NTLA 1.2B
- IPO Year
- REX N/A
- NTLA 2016
- Fundamental
- Price
- REX $30.62
- NTLA $25.74
- Analyst Decision
- REX Strong Buy
- NTLA Buy
- Analyst Count
- REX 1
- NTLA 19
- Target Price
- REX $25.00
- NTLA $30.47
- AVG Volume (30 Days)
- REX 210.5K
- NTLA 7.7M
- Earning Date
- REX 08-27-2025
- NTLA 11-06-2025
- Dividend Yield
- REX N/A
- NTLA N/A
- EPS Growth
- REX N/A
- NTLA N/A
- EPS
- REX 1.49
- NTLA N/A
- Revenue
- REX $650,008,000.00
- NTLA $52,857,000.00
- Revenue This Year
- REX $3.27
- NTLA $9.20
- Revenue Next Year
- REX $17.11
- NTLA N/A
- P/E Ratio
- REX $20.80
- NTLA N/A
- Revenue Growth
- REX N/A
- NTLA 14.99
- 52 Week Low
- REX $16.73
- NTLA $5.90
- 52 Week High
- REX $32.83
- NTLA $26.99
- Technical
- Relative Strength Index (RSI)
- REX 24.98
- NTLA 84.32
- Support Level
- REX $30.30
- NTLA $19.89
- Resistance Level
- REX $32.83
- NTLA $21.49
- Average True Range (ATR)
- REX 0.78
- NTLA 1.73
- MACD
- REX 0.62
- NTLA 0.71
- Stochastic Oscillator
- REX 11.46
- NTLA 86.83
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.